Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease

Paul Albert, Alvar Agusti, Lisa Edwards, Ruth Tal-Singer, Julie Yates, Per Bakke, Bartolome R. Celli, Harvey O. Coxson, Courtney Crim, David A. Lomas, William MacNee, Bruce Miller, Stephen Rennard, Edwin K. Silverman, Jørgen Vestbo, Emiel Wouters, Peter Calverley

Research output: Contribution to journalArticle

112 Scopus citations

Abstract

Background: Bronchodilator responsiveness is a potential phenotypic characteristic of chronic obstructive pulmonary disease (COPD). We studied whether change in lung function after a bronchodilator is abnormal in COPD, whether stable responder subgroups can be identified, and whether these subgroups experience different clinical outcomes. Methods: 1831 patients with COPD, 285 smoking (SC) and 228 non-smoking (NSC) controls from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) cohort. Spirometric reversibility to 400 mg inhaled salbutamol was assessed on four occasions over 1 year. Results: Forced expiratory volume in 1 s (FEV 1) increase after salbutamol was similar in SC (mean 0.14 litres (SD 0.15)) and COPD (0.12 litres (0.15)) and was significantly greater than NSC (0.08 litres (0.14)). Reversibility status varied with repeated testing in parallel with the day-to-day variation in pre-bronchodilator FEV1, which was similar in control subjects and patients with COPD. Absolute FEV1 change decreased by Global initiative for chronic Obstructive Lung Disease (GOLD) stage in patients with COPD (GOLD II, mean 0.16 litres (SD 0.17); III, 0.10 litres (0.13); IV, 0.05 litres (0.08) as did chances of being classified as reversible. CT-defined emphysema was weakly related to the absolute change in FEV1 post salbutamol. Consistently reversible patients (n=227) did not differ in mortality, hospitalisation or exacerbation experience from irreversible patients when allowing for differences in baseline FEV1. Limitations: Reversibility only assessed with salbutamol and defined by FEV1 criteria. The COPD population was older than the control populations. Conclusions: Post-salbutamol FEV1 change is similar in patients with COPD and smoking controls but is influenced by baseline lung function and the presence of emphysema. Bronchodilator reversibility status varies temporally and does not distinguish clinically relevant outcomes, making it an unreliable phenotype. Clinical trial registration number: NCT00292552 (http:// ClinicalTrials.gov).

Original languageEnglish (US)
Pages (from-to)701-708
Number of pages8
JournalThorax
Volume67
Issue number8
DOIs
StatePublished - Aug 2012

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

  • Cite this

    Albert, P., Agusti, A., Edwards, L., Tal-Singer, R., Yates, J., Bakke, P., Celli, B. R., Coxson, H. O., Crim, C., Lomas, D. A., MacNee, W., Miller, B., Rennard, S., Silverman, E. K., Vestbo, J., Wouters, E., & Calverley, P. (2012). Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax, 67(8), 701-708. https://doi.org/10.1136/thoraxjnl-2011-201458